• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

idarucizumab - Articles and news items

Boehringer Ingelheim logo

Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

Industry news / 22 May 2014 / Boehringer Ingelheim

Boehringer Ingelheim announces the next step in the clinical development of idarucizumab, the investigational antidote for rapid reversal of dabigatran-induced anticoagulation…


Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +